Charles Lovell, MD
Internal Medicine · Norfolk, VANPI 1174629448
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Novo Nordisk AS at 25.0% of the total. Reporting peaked in 2019 at $4,517 and has fallen 84.9% since, to $681 in 2025. Among internal medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 264 payments — averaging $54.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$4K
- AstraZeneca$3K
- Novartis$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Boehringer Ingelheim$905
- Corcept Therapeutics$445
- plus $2K from 20 others
Across 1,424 payments — averaging $1286.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$458K
- Novartis$409K
- AstraZeneca$335K
- Sanofi US Services Inc.$144K
- Merck$109K
- Modernatx, Inc.$90K
- plus $287K from 13 others
What the payments were for
- Consulting fees$3,04421%
- Speaking & faculty fees$8766%
- Travel & lodging$4,26630%
- Food & beverage$5,97142%
- Education$1761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 14 | $3,583 |
| AstraZeneca | 48 | $3,341 |
| Novartis | 22 | $2,233 |
| E.r. Squibb & Sons, L.L.C. | 3 | $1,688 |
| Boehringer Ingelheim | 45 | $905 |
| Corcept Therapeutics | 18 | $445 |
| Lilly USA, LLC | 19 | $398 |
| Johnson & Johnson | 13 | $286 |
| Novo Nordisk | 16 | $253 |
| Amgen(2 entities) | 12 | $212 |
| Amarin Pharma, Inc. | 12 | $203 |
| Bayer | 12 | $202 |
| Esperion Therapeutics, Inc. | 3 | $123 |
| Arbor Pharmaceuticals, Inc. | 5 | $59 |
| Vifor Pharma, Inc. | 3 | $59 |
| Alnylam Pharmaceuticals Inc. | 1 | $56 |
| Hikma Pharmaceuticals USA | 3 | $46 |
| Pfizer | 2 | $44 |
| Strongbridge US Inc. | 3 | $41 |
| Radius Health, Inc. | 1 | $27 |
| Livanova USA, Inc. | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Dynavax Technologies Corporation | 2 | $21 |
| Merck | 2 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| AbbVie | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,333 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 49 | $64,556 |
| FarxigaDapagliflozin Propanediol | 55 | $55,155 |
| OzempicSemaglutide | 36 | $49,991 |
| XareltoRivaroxaban | 20 | $28,042 |
| EliquisApixaban | 23 | $22,643 |
| Colchicine | 28 | $6,328 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $5,832 |
| Candesartan Cilexetil | 80 | $5,642 |
| Humalog Kwikpen U-100Insulin Lispro | 23 | $5,262 |
| Nifedipine ErNifedipine | 149 | $4,666 |
| Colesevelam Hcl | 13 | $4,501 |
| Chlorthalidone | 269 | $4,137 |
| Nebivolol Hcl | 62 | $3,501 |
| Ezetimibe | 121 | $3,461 |
| Atorvastatin Calcium | 275 | $2,652 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $398 | $64,55649 claims |
| AstraZenecaFarxiga | $3,341 | $55,15555 claims |
| Novo NordiskOzempic | $253 | $49,99136 claims |
| Johnson & JohnsonXarelto | $286 | $28,04220 claims |
| PfizerEliquis | $44 | $22,64323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Norfolk
- Kunal KapoorNorfolk$34K
- Prashant BarakotiNorfolk$17K
- Kristina KratovilNorfolk$15K
- Kumar AbhishekMechanicsville$1M
- Amit MahajanFalls Church$1M
- Kevin DonohueFalls Church$655K
- Denise BrunerArlington$227K
- Anjali KaloreMidlothian$215K
- Scott GerrishVienna$207K
- Lawrence SchwartzRichmond$205K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.